BC Week In Review | Nov 30, 2017
Clinical News

Amplyx reports Phase I data for APX001 in fungal infections

In October, Amplyx Pharmaceuticals Inc. (San Diego, Calif.) reported data from two Phase I trials in 166 healthy volunteers showing that oral and IV APX001 were well tolerated at all doses tested. Additionally, the company...
BioCentury | Aug 4, 2017

Fungal flexibility

Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001. On Aug. 2, the biotech raised $67 million...
BC Extra | Aug 2, 2017
Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital, and existing...
BC Week In Review | Sep 19, 2016
Clinical News

IV APX001: Phase I started

Amplyx began a double-blind, placebo-controlled, dose-escalation, European Phase I trial to evaluate single and multiple doses of IV APX001 in about 80 healthy volunteers. The company plans to begin Phase I testing of oral APX001...
BC Week In Review | Jun 20, 2016
Clinical News

APX001 regulatory update

Amplyx Pharmaceuticals Inc. , San Diego, Calif.   Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan   Product: APX001   Business: Infectious   FDA granted Qualified Infectious Disease Product (QIDP) designation to APX001 from Amplyx to treat 3...
BioCentury | Nov 16, 2015

Clinical catalyst

After in-licensing an antifungal for $1.5 million in January, Amplyx Pharmaceuticals Inc. has used the asset to attract its first venture money in over five years and recruit a new management team focused on product...
BC Extra | Nov 12, 2015
Financial News

Amplyx raises $40.5M series B

Amplyx Pharmaceuticals Inc. raised $40.5 million in a series B round led by RiverVest Venture Partners. Other investors included New Enterprise Associates, BioMed Ventures and undisclosed individuals. Next year, the company plans to start Phase...
BC Week In Review | Jun 29, 2015
Company News

Apexigen Inc., 3SBio deal

Apexigen granted 3SBio rights outside of China to SSS07 . 3SBio already held rights in China to the humanized mAb that inhibits tumor necrosis factor (TNF) alpha under a 2006 deal. The companies declined to disclose...
BC Extra | Jun 23, 2015
Company News

3SBio gets worldwide rights to Apexigen's anti-TNF

3SBio Inc. (HKSE:1530) received ex-China rights to SSS07 from Apexigen Inc. (San Carlos, Calif.). 3SBio already held rights in China to the humanized mAb that inhibits tumor necrosis factor (TNF) alpha. Neither company would disclose...
Items per page:
1 - 9 of 9